Skip to main content
Fujian Haixi Pharmaceuticals Co., Ltd. logo

Fujian Haixi Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2637 ISIN · CNE100007515 HKEX Manufacturing
Open in API
Filings indexed 38 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2637

About Fujian Haixi Pharmaceuticals Co., Ltd.

http://www.hxpharma.com

Fujian Haixi Pharmaceuticals Co., Ltd. is a commercial-stage pharmaceutical company integrating R&D, production, and sales capabilities. The company operates primarily under the Market Authorization Holder (MAH) framework, enabling an asset-light business model. Haixi Pharma pursues a dual-line development strategy, balancing generic drugs and innovative drugs. Its generic portfolio emphasizes first-to-file, difficult-to-imitate, and high-quality products, leveraging national pharmaceutical policies. As of late 2025, the company had 15 approved generic drugs commercialized, primarily targeting digestive system diseases and cardiovascular system diseases, with a broader therapeutic scope including oncology, ophthalmology, endocrine, nervous systems, and inflammation. The innovative drug pipeline focuses on developing small-molecule drugs with significant unmet medical needs and global market potential, exemplified by its lead program, C019199.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in authorized and issued shares, public float sufficiency confirmation, and other share capital related information. It is a regulatory compliance report submitted to the exchange, not a financial report, earnings release, or management discussion. The document is structured as a formal regulatory submission with no financial statements or management commentary. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share capital and public float compliance, not a report publication announcement or a detailed financial report.
2026-05-07 English
PROXY FORM FOR THE ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a proxy form for the Annual General Meeting (AGM) of Fujian Haixi Pharmaceuticals Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including approval of the 2025 Annual Report, election of directors, amendments to articles, and other corporate matters. The document is not the Annual Report itself but a form used to facilitate voting at the AGM. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms. The document length is 9780 characters, which is consistent with a detailed proxy form rather than a brief announcement or a full report. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-30 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of the Annual General Meeting (AGM) for Fujian Haixi Pharmaceuticals Co., Ltd. It includes details about the date, location, agenda items such as approval of the 2025 Annual Report, election of directors, and other resolutions to be considered at the AGM. The document does not contain the actual annual report or financial statements but rather the notice to shareholders about the meeting and the items to be voted on. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices of the AGM itself. The document length is 8161 characters, which is consistent with a detailed AGM notice. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-30 English
2025 AGM Circular
AGM Information Classification · 95% confidence The document is a circular for the Annual General Meeting (AGM) of Fujian Haixi Pharmaceuticals Co., Ltd. It includes detailed agenda items such as the work reports of the Board of Directors and Board of Supervisors, audited consolidated financial statements, the annual report and ESG report for 2025, profit distribution plan, re-appointment of external auditor, amendments to articles of association, and other governance matters. The document also contains the notice of the AGM and proxy form instructions. The presence of detailed reports and proposals to be approved at the AGM, along with the notice and proxy form, indicates this is a circular related to the AGM, containing materials shared for the meeting. It is not the annual report itself, nor a simple announcement of a report publication. Therefore, the document fits the category of AGM Information (AGM-R).
2026-04-30 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 90% confidence The document is a full-length Environmental, Social and Governance (ESG) report covering sustainability strategy, ESG KPIs, governance practices, and Hong Kong Stock Exchange ESG Reporting Code compliance. It is not an announcement of a report but the report itself, matching the definition of Environmental & Social Information (Code: SR).
2026-04-29 English
ANNUAL REPORT 2025
Regulatory Filings
2026-04-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.